Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis

Carsten Hjorthøj, Allan Fohlmann, Anne-Mette Larsen, Mette T R Madsen, Lone Vesterager, Christian Gluud, Mikkel C Arendt, Merete Nordentoft, Carsten Hjorthøj, Allan Fohlmann, Anne-Mette Larsen, Mette T R Madsen, Lone Vesterager, Christian Gluud, Mikkel C Arendt, Merete Nordentoft

Abstract

Background: A number of studies indicate a link between cannabis-use and psychosis as well as more severe psychosis in those with existing psychotic disorders. There is currently insufficient evidence to decide the optimal way to treat cannabis abuse among patients with psychosis.

Objectives: The major objective for the CapOpus trial is to evaluate the additional effect on cannabis abuse of a specialized addiction treatment program adding group treatment and motivational interviewing to treatment as usual.

Design: The trial is designed as a randomized, parallel-group, observer-blinded clinical trial. Patients are primarily recruited through early-psychosis detection teams, community mental health centers, and assertive community treatment teams. Patients are randomized to one of two treatment arms, both lasting six months: 1) specialized addiction treatment plus treatment as usual or 2) treatment as usual. The specialized addiction treatment is manualized and consists of both individual and group-based motivational interviewing and cognitive behavioral therapy, and incorporates both the family and the case manager of the patient.The primary outcome measure will be changes in amount of cannabis consumption over time. Other outcome measures will be psychosis symptoms, cognitive functioning, quality of life, social functioning, and cost-benefit analyses.

Trial registration: ClinicalTrials.gov NCT00484302.

Figures

Figure 1
Figure 1
Flowchart of the CapOpus trial. See text for further information.
Figure 2
Figure 2
Schematic timeline of the CapOpus intervention.
Figure 3
Figure 3
Assessment tools used in the CapOpus trial.

References

    1. Moore THM, Zammit S, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319–328. doi: 10.1016/S0140-6736(07)61162-3.
    1. Nordentoft M, Hjorthøj C. Cannabis use and risk of psychosis in later life. Lancet. 2007;370:293–294. doi: 10.1016/S0140-6736(07)61135-0.
    1. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325:1199. doi: 10.1136/bmj.325.7374.1199.
    1. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004;184:110–117. doi: 10.1192/bjp.184.2.110.
    1. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325:1212–1213. doi: 10.1136/bmj.325.7374.1212.
    1. Henquet C, Murray R, Linszen D, van OJ. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31:608–612. doi: 10.1093/schbul/sbi027.
    1. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van OJ. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330:11. doi: 10.1136/bmj.38267.664086.63.
    1. Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004;99:425–430. doi: 10.1111/j.1360-0443.2004.00683.x.
    1. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, van OJ. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction. 2004;99:1333–1341. doi: 10.1111/j.1360-0443.2004.00806.x.
    1. Hall W. Is cannabis use psychotogenic? Lancet. 2006;367:193–195. doi: 10.1016/S0140-6736(06)68012-4.
    1. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273–279.
    1. Grech A, van OJ, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry. 2005;20:349–353. doi: 10.1016/j.eurpsy.2004.09.013.
    1. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry. 2006;189:137–143.
    1. van Os J, Bak M, Hanssen M, Bijl RV, de GR, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156:319–327. doi: 10.1093/aje/kwf043.
    1. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci. 1999;249:45–49. doi: 10.1007/s004060050064.
    1. Kamali M, Kelly L, Gervin M, Browne S, Larkin C, O'Callaghan E. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. Psychiatr Serv. 2001;52:161–166. doi: 10.1176/appi.ps.52.2.161.
    1. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting Medication Noncompliance After Hospital Discharge Among Patients With Schizophrenia. Psychiatr Serv. 2000;51:216–222. doi: 10.1176/appi.ps.51.2.216.
    1. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637–651.
    1. Wilk J, Marcus SC, West J, Countis L, Hall R, Regier DA, Olfson M. Substance abuse and the management of medication nonadherence in schizophrenia. J Nerv Ment Dis. 2006;194:454–457. doi: 10.1097/01.nmd.0000221289.54911.63.
    1. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica. 2002;106:286–290. doi: 10.1034/j.1600-0447.2002.02437.x.
    1. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd. New York, Guilford; 2002.
    1. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, Schofield N, McGovern J. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry. 2001;158:1706–1713. doi: 10.1176/appi.ajp.158.10.1706.
    1. RachBeisel J, Scott J, Dixon L. Co-occurring severe mental illness and substance use disorders: a review of recent research. Psychiatr Serv. 1999;50:1427–1434.
    1. Ziedonis DM. Integrated treatment of co-occurring mental illness and addiction: clinical intervention, program, and system perspectives. CNS Spectr. 2004;9:892–904, 925.
    1. Weiss RD, Mirin SM, Griffin ML. Methodological considerations in the diagnosis of coexisting psychiatric disorders in substance abusers. Br J Addict. 1992;87:179–187. doi: 10.1111/j.1360-0443.1992.tb02691.x.
    1. McRobert C, Burlingame GM, Hoag MJ. Comparative efficacy of individual and group psychotherapy: A meta-analytic perspective. Group Dynamics: Theory, Research, and Practice. 1998;2:101–117. doi: 10.1037/1089-2699.2.2.101.
    1. Greene LR. Research in Group Psychotherapy for Substance Abuse: Fiction, Fact, and Future. In: Brook DW and Spitz HI, editor. The Group Therapy for Substance Abuse. New York, The Haworth Medical Press; 2002. pp. 391–410.
    1. Cleary M, Hunt G, Matheson S, Siegfried N, Walter G. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2008:CD001088.
    1. Sobell LC, Sobell MB. Timeline Follow-Back: A Technique for Assessing Self-Reported Alcohol Consumption. In: Litten RZ and Allen J, editor. Measuring Alcohol Consumption: Psychosocial and Biological Methods. New Jersey, Humana Press; 1992. pp. 41–72.
    1. Donohue B, Hill HH, Azrin NH, Cross C, Strada MJ. Psychometric support for contemporaneous and retrospective youth and parent reports of adolescent marijuana use frequency in an adolescent outpatient treatment population. Addictive Behaviors. 2007;32:1787–1797. doi: 10.1016/j.addbeh.2006.12.005.
    1. Miller WR. Motivational Interviewing. Behav Psychother. 1983;11:91–111.
    1. Hettema J, Steele J, Miller WR. Motivational interviewing. Annual Review of Clinical Psychology. 2005;1:91–111. doi: 10.1146/annurev.clinpsy.1.102803.143833.
    1. Burke BL, Arkowitz H, Menchola M. The efficacy of motivational interviewing: a meta-analysis of controlled clinical trials. J Consult Clin Psychol. 2003;71:843–861. doi: 10.1037/0022-006X.71.5.843.
    1. Denis C, Lavie E, Fatseas M, Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev. 2006;3:CD005336.
    1. Jørgensen P, Nordentoft M, Abel MB, Gouliaev G, Jeppesen P, Kassow P. Early detection and assertive community treatment of young psychotics: the Opus Study Rationale and design of the trial. Soc Psychiatry Psychiatr Epidemiol. 2000;35:283–287. doi: 10.1007/s001270050240.
    1. Nordentoft M, Knudsen HC, Jessen-Petersen B, Krasnik A, Sælan H, Treufeldt P, Wetcher B. CCPP-Copenhagen Community Psychiatric Project. Implementation of community mental health centres in Copenhagen: effects of service utilization, social integration, quality of life and positive and negative symptoms. Soc Psychiatry Psychiatr Epidemiol. 1996;31:336–344. doi: 10.1007/BF00783422.
    1. Vendsborg P, Nordentoft M, Hvenegaard A, Søgaard J. Opsøgende psykoseteam: Assertive Community Treatment. Copenhagen, Institut for sundhedsvæsen; 1999.
    1. Petersen L, Jeppesen P, Thorup A, Abel MB, Ohlenschlaeger J, Christensen TO, Krarup G, Jorgensen P, Nordentoft M. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ. 2005;331:602. doi: 10.1136/bmj.38565.415000.E01.
    1. WHO International Classification of Diseases (ICD) 2007.
    1. Thorup A, Waltoft BL, Pedersen CB, Mortensen PB, Nordentoft M. Young males have a higher risk of developing schizophrenia: a Danish register study. Psychol Med. 2007;37:479–484. doi: 10.1017/S0033291707009944.
    1. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990;47:589–593.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
    1. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: Clinical Implications. Neuropsychopharmacology. 2006;31:2318–2325. doi: 10.1038/sj.npp.1300873.
    1. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophrenia Research. 2005;79:231–238. doi: 10.1016/j.schres.2005.04.008.
    1. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI. Schizophrenia Research. 2008;98:318–322. doi: 10.1016/j.schres.2007.09.006.
    1. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766–771.
    1. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association; 1994.
    1. Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex. 1978;14:234–244.
    1. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research. 2004;68:283–297. doi: 10.1016/j.schres.2003.09.011.
    1. Bowie CR, Harvey PD. Administration and interpretation of the Trail Making Test. Nat Protocols. 2006;1:2277–2281. doi: 10.1038/nprot.2006.390.
    1. Spreen O, Strauss A. A Compendium of Neuropsychological Test Administration, Norms, and Commentary. New York, Oxford University Press; 1998.
    1. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Research. 1989;29:65–85. doi: 10.1016/0165-1781(89)90188-1.
    1. Brandt J. The Hopkins verbal learning test : development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5:125–142. doi: 10.1080/13854049108403297.
    1. Stern RA, White T. Neuropsychological Assessment Battery. Lutz, Florida, Psychological Assessment Resources, Inc.; 2003.
    1. WHO . World Health Organization Disability Assessment Schedule (WHODAS II) Geneva, WHO; 2000.
    1. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53–72. doi: 10.1016/0168-8510(96)00822-6.
    1. Priebe S, Huxley P, Knight S, Evans S. Application and Results of the Manchester Short Assessment of Quality of Life (Mansa) International Journal of Social Psychiatry. 1999;45:7–12. doi: 10.1177/002076409904500102.
    1. Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: Development of a general scale. Evaluation and Program Planning. 1979;2:197–207. doi: 10.1016/0149-7189(79)90094-6.
    1. Munk-Jørgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44:82–84.
    1. Munk-Jørgensen P, Kastrup M, Mortensen PB. The Danish psychiatric register as a tool in epidemiology. Acta Psychiatr Scand Suppl. 1993;370:27–32. doi: 10.1111/j.1600-0447.1993.tb05358.x.
    1. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263–268.
    1. Pedersen CB, Gøtzsche H, Møller J, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53:441–449.
    1. Cohen J. A Coefficient of Agreement for Nominal Scales. Educational and Psychological Measurement. 1960;20:37–46. doi: 10.1177/001316446002000104.
    1. Haddock G, Barrowclough C, Tarrier N, Moring J, O'Brien R, Schofield N, Quinn J, Palmer S, Davies L, Lowens I, McGovern J, Lewis S. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. Br J Psychiatry. 2003;183:418–426. doi: 10.1192/bjp.183.5.418.
    1. Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. Br J Psychiatry. 2006;188:439–448. doi: 10.1192/bjp.188.5.439.
    1. Baker A, Bucci S, Lewin TJ, Richmond R, Carr VJ. Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies. Psychiatry Res. 2005;134:241–250. doi: 10.1016/j.psychres.2005.02.006.
    1. Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006;63:426–432. doi: 10.1001/archpsyc.63.4.426.
    1. Lachin JM. Statistical Considerations in the Intent-to-Treat Principle. Controlled Clinical Trials. 2000;21:167–189. doi: 10.1016/S0197-2456(00)00046-5.
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357:1191–1194. doi: 10.1016/S0140-6736(00)04337-3.
    1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, for the CONSORT Group Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration. Ann Intern Med. 2008;148:295–309.
    1. Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 2006;163:493–501. doi: 10.1093/aje/kwj069.
    1. Gluud C. The culture of designing hepato-biliary randomised trials. J Hepatol. 2006;44:607–615. doi: 10.1016/j.jhep.2005.12.006.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj